These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 29802568)
1. The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine. Wei D; Yu W; Hu C; Shen L; Hu T Biotechnol Lett; 2018 Aug; 40(8):1263-1270. PubMed ID: 29802568 [TBL] [Abstract][Full Text] [Related]
2. Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine. Chang X; Yu W; Ji S; Shen L; Tan A; Hu T Vaccine; 2017 Mar; 35(13):1698-1704. PubMed ID: 28242069 [TBL] [Abstract][Full Text] [Related]
3. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine. Zhang T; Yu W; Wang Y; Hu T Vaccine; 2015 Jun; 33(28):3208-14. PubMed ID: 25964170 [TBL] [Abstract][Full Text] [Related]
4. Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm. Wu D; Ji S; Hu T Vaccine; 2013 Nov; 31(48):5623-6. PubMed ID: 24120485 [TBL] [Abstract][Full Text] [Related]
5. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine. Qiao W; Ji S; Zhao Y; Hu T Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319 [TBL] [Abstract][Full Text] [Related]
6. The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity. Yu R; Xu J; Hu T; Chen W Mediators Inflamm; 2020; 2020():9596129. PubMed ID: 32714092 [TBL] [Abstract][Full Text] [Related]
7. Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model. Mawas F; Feavers IM; Corbel MJ Vaccine; 2000 Dec; 19(9-10):1159-66. PubMed ID: 11137252 [TBL] [Abstract][Full Text] [Related]
8. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine. Huang Q; Li D; Kang A; An W; Fan B; Ma X; Ma G; Su Z; Hu T J Control Release; 2013 Nov; 172(1):382-389. PubMed ID: 23511718 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D; Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207 [TBL] [Abstract][Full Text] [Related]
10. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Buchwald UK; Lees A; Steinitz M; Pirofski LA Infect Immun; 2005 Jan; 73(1):325-33. PubMed ID: 15618169 [TBL] [Abstract][Full Text] [Related]
11. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Boutonnier A; Villeneuve S; Nato F; Dassy B; Fournier JM Infect Immun; 2001 May; 69(5):3488-93. PubMed ID: 11292781 [TBL] [Abstract][Full Text] [Related]
12. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. Kamboj KK; Kirchner HL; Kimmel R; Greenspan NS; Schreiber JR J Infect Dis; 2003 May; 187(10):1629-38. PubMed ID: 12721943 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide. Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445 [TBL] [Abstract][Full Text] [Related]
15. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Soininen A; Seppälä I; Nieminen T; Eskola J; Käyhty H Vaccine; 1999 Apr; 17(15-16):1889-97. PubMed ID: 10217586 [TBL] [Abstract][Full Text] [Related]
16. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies. da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805 [TBL] [Abstract][Full Text] [Related]
17. Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate. Lu CH; Lee CJ; Kind P Infect Immun; 1994 Jul; 62(7):2754-60. PubMed ID: 8005665 [TBL] [Abstract][Full Text] [Related]
18. Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines. Lockyer K; Gao F; Derrick JP; Bolgiano B Vaccine; 2015 Mar; 33(11):1345-52. PubMed ID: 25640334 [TBL] [Abstract][Full Text] [Related]
19. Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM₁₉₇ conjugate vaccine. Lai Z; Schreiber JR Clin Vaccine Immunol; 2011 May; 18(5):724-9. PubMed ID: 21450979 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Lee CJ; Wang TR; Frasch CE Vaccine; 2001 Apr; 19(23-24):3216-25. PubMed ID: 11312018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]